The Xenazine Model: Big Things Come In Small Packages
Executive Summary
The Huntington's chorea therapy Xenazine (tetrabenazine) is being used by just over 1,000 patients after three months on the market, and Biovail couldn't be happier
You may also be interested in...
Non-Profit CHDI Taps Galapagos For Developing Huntington's Disease Therapy
The philanthropy firm, like others of its ilk, seeks to accelerate early-stage R&D on a neglected disease.
Biovail Walks The Walk: More CNS Licensing, Acquisitions Planned For 2010
Biovail is putting its money where its mouth is. The Toronto-based specialty pharma announced plans early in 2008 to turn itself into a specialty central nervous system company, and - after five deals in 18 months -Biovail execs are more excited than ever about the opportunities open to them
Biovail Walks The Walk: More CNS Licensing, Acquisitions Planned For 2010
Biovail is putting its money where its mouth is. The Toronto-based specialty pharma announced plans early in 2008 to turn itself into a specialty central nervous system company, and - after five deals in 18 months -Biovail execs are more excited than ever about the opportunities open to them